DNA Quantification via Ligation Oligonucleotides and UMIs

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for quantifying DNA sequences face challenges such as unbalanced amplification leading to biased detection and lower sequencing coverage due to the transfer of only an aliquot of ligated products to the amplification step, resulting in allelic drop-out and PCR-induced bias.

Innovation Solution

A method involving contacting target DNA sequences with left and right ligation oligonucleotides, followed by ligation, immobilization, and amplification using unique molecular identifiers (UMIs) and barcodes to enable absolute molecule counting and maximize sequencing coverage, while minimizing PCR bias.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If an aliquot of ligated products is transferred to the amplification step, then the process is simplified, but sequencing coverage is reduced and allelic drop-out occurs

Engineering Contradiction:
Improveprocess simplicityVSAvoidsequencing coverage
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The patent applies preliminary action by performing ligation of oligonucleotides to target DNA sequences before the amplification step. This ensures that all target sequences are pre-assembled with their corresponding oligonucleotides, preventing allelic drop-out during subsequent amplification and maximizing sequencing coverage while maintaining process simplicity

Inventive Principle:
Principle #10Preliminary action

2Measurement precision

If PCR amplification is used to multiply original nucleic acid molecules, then detection sensitivity is improved, but PCR-induced bias and unspecific amplification occur

Engineering Contradiction:
Improvedetection sensitivityVSAvoidamplification accuracy
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent uses ligated oligonucleotide products as intermediaries between the target DNA sequences and the PCR amplification process. These pre-ligated products serve as specific templates that reduce unspecific amplification and PCR-induced bias while maintaining detection sensitivity, as they contain unique molecular identifiers that enable accurate quantification

Inventive Principle:
Principle #24Intermediary (Mediator)

3Measurement precision

If unique molecular identifiers are incorporated into ligation oligonucleotides, then absolute molecule counting is enabled, but the complexity of the assay increases

Engineering Contradiction:
Improvequantification accuracyVSAvoidassay complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses unique molecular identifiers (UMIs) as digital copies or tags associated with each original DNA molecule. During amplification, these UMIs are replicated along with the target sequence, allowing bioinformatic tools to group and count reads by their UMI identifiers, thereby enabling absolute molecule counting without significantly increasing wet-lab procedural complexity

Inventive Principle:
Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for accurate and absolute quantification of target DNA sequences with high specificity and sensitivity, ensuring maximum coverage of unique DNA molecules and eliminating unspecific amplification, thereby overcoming the limitations of prior art techniques.

Implementation Method 1

contacting, in each container of N separate containers, target DNA sequences, under hybridization conditions, with M L left ligation oligonucleotides and M R right ligation oligonucleotides

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

adding, in each container of the N separate containers, a ligating agent capable of ligating together the 3' end of a left ligation oligonucleotide and the 5' end of a right ligation oligonucleotide while hybridized to a target DNA sequence to form a ligated product

Methodology Applied
Scientific EffectLigation:

Implementation Method 3

immobilizing, in each container of the N separate containers, the ligated product in complex with the target DNA sequence onto a solid phase having preference for DNA sequences

Methodology Applied
Scientific EffectAdsorption: Adsorption

Implementation Method 4

amplifying, in each container of the N separate containers, the ligated product in presence of a left amplification primer and a right amplification primer to form an amplified product comprising two UMIs and one barcode sequence

Methodology Applied
Scientific EffectPCR amplification:

Data Source

PatentEP3565906B1Quantifying DNA sequences
Publication Date: 2021.01.27 TERVISETEHNOLOOGIATE ARENDUSKESKUS AS
  • EP3565906B1 patent drawingFigure 1A~1C
  • EP3565906B1 patent drawingFigure 1D~1E
  • EP3565906B1 patent drawingFigure 2~3

AI summary

A target DNA sequence (1 ) is contacted with ML+MR ligation oligonucleotides (10, 20) under hybridization conditions. The ligation oligonucleotides (10, 20) comprises a respective UMI (14, 15). A ligating agent ligates together the ligation oligonucleotides (10, 20) while hybridized to the target DNA sequence (1) to form a ligated product (30). The ligated product (30) is amplified by means to amplification primers (40, 50), of which one comprises a sample-specific barcode sequence (55), to form an amplified product (60) comprising two UMIs (65), a sequence of interest (66) and one barcode sequence (68). Amplified products (60) from multiple samples are pooled together, sequenced, demultiplexed and mapped to enable quantification of unique target DNA sequences (1) in the different samples.